ArticleDrug delivery2017
Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB
Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 85 citations in OpenAlex.
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
- Emerging roles of SLC6A14 in digestive system diseases: from amino acid transport to therapeutic targeting.Molecular biology reports · 2026Review
- Lipopeptides fromBiotech (Basel (Switzerland)) · 2026Article
- Navigating Cancer Treatment: A Journey from 2D to 3D Cancer Models and Nanoscale Therapies.ACS pharmacology & translational science · 2025Review
- Amino Acid Transporters in Glioblastoma: Implications for Diagnosis, Disease Monitoring, Therapeutic Targeting, and Drug Delivery.Molecular diagnosis & therapy · 2025Review
- Dysfunction of the carnitine cycle in tumor progression.Heliyon · 2024Review
- OCTN2- and ATBJournal of nanobiotechnology · 2024Article
- A New Paradigm in Spinal Cord Injury Therapy: from Cell-free Treatment to Engineering Modifications.CNS & neurological disorders drug targets · 2024Review
- Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis.Drug delivery · 2023Article
- RETRACTED: Assessing the In Vitro and In Vivo Performance of L-Carnitine-Loaded Nanoparticles in Combating Obesity.Molecules (Basel, Switzerland) · 2023Article
- Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically.Journal of pharmaceutical analysis · 2023Article
- Transporter-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2023Review
- Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation.Oxidative medicine and cellular longevity · 2023Review
- L-Carnitine Functionalization to Increase Skeletal Muscle Tropism of PLGA Nanoparticles.International journal of molecular sciences · 2022Article
- Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy.Journal of nanobiotechnology · 2021Article
- Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies.Theranostics · 2021Review
- OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug deliveryDrug delivery · 2020Article
- Drug discovery and formulation development for acute pancreatitis.Drug delivery · 2020Review
- Verticillin A inhibits colon cancer cell migration and invasion by targeting c-Met.Journal of Zhejiang University. Science. B · 2020Article
- Transporter-Targeted Nano-Sized Vehicles for Enhanced and Site-Specific Drug Delivery.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
l-Carnitine, obligatory for oxidation of fatty acids, is transported into cells by the Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.